Literature DB >> 19588213

Does myocardial perfusion scintigraphy predict improvement in symptoms and exercise capacity following successful elective percutaneous coronary intervention?

M Bashar Al-Housni1, Fiona Hutchings, Miles Dalby, Michael Dubowitz, Richard Grocott-Mason, Charles D J Ilsley, Mark Mason, Andrew G Mitchell, Andrew D Kelion.   

Abstract

BACKGROUND: Elective percutaneous coronary intervention (PCI) without inducible ischaemia may not be beneficial. We investigated the prevalence of inducible hypoperfusion using myocardial perfusion scintigraphy (MPS) in patients undergoing PCI, and its ability to predict functional outcome. METHODS AND
RESULTS: One hundred and twenty-three patients listed for elective PCI underwent MPS, using treadmill exercise where possible. Seventy-seven patients (63%) described chest pain in daily life. Seventy-four of 103 (72%) exercise ECG tests were positive. Ninety-one (74%) had inducible hypoperfusion on MPS (extensive in 25; 20%). Interventionalists were blinded to the scintigraphic results, and PCI was performed as planned. Six months later, Seattle Angina Questionnaire physical limitation score had improved from 66 to 76 (P < 0.0001), and peak treadmill workload from 7.2 +/- 2.3 to 9.0 +/- 2.7 METS (P < 0.0001). Sex, limiting chest pain on baseline exercise testing, and MPS summed difference score (SDS) were independent predictors of improvement. Patients with both limiting chest pain and SDS > or = 7 demonstrated an increase of 3.3 +/- 1.8 METS, compared with approximately 1.5 METS for other subgroups (P < 0.05).
CONCLUSIONS: Many patients undergoing elective PCI in a UK centre have little or no evidence of inducible hypoperfusion. The combination of limiting chest pain during exercise testing and significant inducible hypoperfusion on MPS predicts a large increase in exercise capacity after PCI.

Entities:  

Mesh:

Year:  2009        PMID: 19588213     DOI: 10.1007/s12350-009-9112-y

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  18 in total

1.  Sex differences in investigation results and treatment in subjects referred for investigation of chest pain.

Authors:  Y Wong; A Rodwell; S Dawkins; S A Livesey; I A Simpson
Journal:  Heart       Date:  2001-02       Impact factor: 5.994

2.  Correspondence between left ventricular 17 myocardial segments and coronary arteries.

Authors:  Osvaldo Pereztol-Valdés; Jaume Candell-Riera; César Santana-Boado; Juan Angel; Santiago Aguadé-Bruix; Joan Castell-Conesa; Ernest V Garcia; Jordi Soler-Soler
Journal:  Eur Heart J       Date:  2005-09-23       Impact factor: 29.983

3.  A clinically relevant classification of chest discomfort.

Authors:  G A Diamond
Journal:  J Am Coll Cardiol       Date:  1983-02       Impact factor: 24.094

4.  Use of myocardial perfusion imaging to predict the effectiveness of coronary revascularisation in patients with stable angina pectoris.

Authors:  Allan Johansen; Poul Flemming Høilund-Carlsen; Henrik Wulff Christensen; Werner Vach; Mette Møldrup; Torben Haghfelt
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-04-12       Impact factor: 9.236

5.  The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis.

Authors:  Timothy D Henry; Brian H Annex; George R McKendall; Michael A Azrin; John J Lopez; Frank J Giordano; P K Shah; James T Willerson; Raymond L Benza; Daniel S Berman; C Michael Gibson; Alex Bajamonde; Amy Chen Rundle; Jennifer Fine; Edward R McCluskey
Journal:  Circulation       Date:  2003-03-18       Impact factor: 29.690

6.  Independent and incremental prognostic value of exercise single-photon emission computed tomographic (SPECT) thallium imaging in coronary artery disease.

Authors:  A S Iskandrian; S C Chae; J Heo; C D Stanberry; V Wasserleben; V Cave
Journal:  J Am Coll Cardiol       Date:  1993-09       Impact factor: 24.094

7.  A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.

Authors:  Marie-Claude Morice; Patrick W Serruys; J Eduardo Sousa; Jean Fajadet; Ernesto Ban Hayashi; Marco Perin; Antonio Colombo; G Schuler; Paul Barragan; Giulio Guagliumi; Ferenc Molnàr; Robert Falotico
Journal:  N Engl J Med       Date:  2002-06-06       Impact factor: 91.245

8.  Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease.

Authors:  J A Spertus; J A Winder; T A Dewhurst; R A Deyo; J Prodzinski; M McDonell; S D Fihn
Journal:  J Am Coll Cardiol       Date:  1995-02       Impact factor: 24.094

9.  Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy.

Authors:  Leslee J Shaw; Daniel S Berman; David J Maron; G B John Mancini; Sean W Hayes; Pamela M Hartigan; William S Weintraub; Robert A O'Rourke; Marcin Dada; John A Spertus; Bernard R Chaitman; John Friedman; Piotr Slomka; Gary V Heller; Guido Germano; Gilbert Gosselin; Peter Berger; William J Kostuk; Ronald G Schwartz; Merill Knudtson; Emir Veledar; Eric R Bates; Benjamin McCallister; Koon K Teo; William E Boden
Journal:  Circulation       Date:  2008-02-11       Impact factor: 29.690

Review 10.  Myocardial perfusion scintigraphy: the evidence.

Authors:  S R Underwood; C Anagnostopoulos; M Cerqueira; P J Ell; E J Flint; M Harbinson; A D Kelion; A Al-Mohammad; E M Prvulovich; L J Shaw; A C Tweddel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02       Impact factor: 9.236

View more
  2 in total

1.  Growing evidence that radionuclide imaging identifies management strategies that improve outcome.

Authors:  Michael R Freeman
Journal:  J Nucl Cardiol       Date:  2009-07-28       Impact factor: 5.952

2.  Outcome of revascularisation in stable coronary artery disease without ischaemia: a Danish registry-based follow-up study.

Authors:  Jane Angel Simonsen; Hans Mickley; Allan Johansen; Søren Hess; Anders Thomassen; Oke Gerke; Lisette O Jensen; Jesper Hallas; Werner Vach; Poul F Hoilund-Carlsen
Journal:  BMJ Open       Date:  2017-08-11       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.